EN DE
Watch BeOne Medicines AG for free: we tell you when fair value or trend changes.
Data-driven stock valuation

BeOne Medicines AG (6160) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of BeOne Medicines AG stock HK$153, price HK$248, that is 38.4% below the price, quality 76 out of 100. Rating: strongly overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in Switzerland · ISIN KYG1146Y1017

BM BeOne Medicines AG logo Some data Nov 9, 2026

BeOne Medicines AG

6160 · HK
Strong quality, but very expensive

Our calculation puts a fair price 38% below what the stock costs today.

Quality 76/100
Solidly profitable · 13.9% net margin (TTM)
Low debt
Generates free cash flow
Positive coverage
Revenue last quarter +34% vs. a year ago.
Mixed Growth (revenue 5y +76.9 %/yr in USD)
Mixed vs. peers (8/14)
Moderate moat 64/100
Some data
Fair value HK$152.80 · Strongly overvalued
Quality growth

Risks from the AI analysis

🚩Geopolitical and regulatory risks from China ties🚩Generic competition to Brukinsa after settlement
Watch BeOne Medicines AG for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$278.60 HK$74.35 Fair Value HK$152.80 Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.

How to read this chart

60‑month range HK$74.35 – HK$278.60 · fair‑value band HK$106.96 – HK$198.64 · the HK$248.20 price screens above the HK$152.80 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.

Follow BeOne Medicines in your weekly email

Every Wednesday you see whether BeOne Medicines is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.

Show moreShow less

The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors.

Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs.

The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

Stock analysis

BeOne Medicines AG (6160) currently trades at HK$248.20, while our model-based Fair Value estimate is HK$152.80, 38% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of HK$151.16 per share, and 0 of the 24 models we run sit above the HK$248.20 price.

Bear case: the Economic Profit group reads lowest at HK$37.96, and 24 of the 24 models stay below the price. Data coverage for this calculation is medium.

Scenario range: HK$106.96 (bear) to HK$198.64 (bull), the price of HK$248.20 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 76/100 (high quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

BeOne Medicines AG reported revenue of $5.4B in FY2025 versus $1.2B in FY2021, a compound +46.0%/yr. Reported net income was $287M in FY2025.

Key figures

Market cap HK$374B (≈ $47.7B) Large · P/E ratio 52.1 · P/S ratio 2.80 · EPS (TTM) HK$2.76 · Net margin 5.4% · Return on equity 18.4% · Return on assets (EBIT) −13.9% (5-year average) · Operating margin 22.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 64 out of 100 (medium confidence).

What moves the price

Analysts expect earnings well below the last reported figure (earnings in transition, for example expiring patents or contracts); a fair value that looks fair on trailing earnings may then be too optimistic.

The share trades at its 52-week high and 60% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −38%, 6160 screens richer than that median.

Fair Value models

Bear HK$106.96 Fair Value HK$152.80 Bull HK$198.64
Price HK$248.20 · Downside -38.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (HK$2.37 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF HK$116.94 HK$172.95 HK$352.35 74
EPV HK$38.28 HK$41.24 HK$43.84 74
Growth DCF HK$111.27 HK$202.39 HK$352.47 73
All 24 models by family
DCF Models
FCF DCF HK$116.94 HK$172.95 HK$352.35 74
Owner Earnings HK$64.09 HK$120.04 HK$238.65 70
5Y Revenue Exit HK$65.78 HK$89.83 HK$139.43 70
5Y EBITDA Exit HK$73.72 HK$105.88 HK$168.63 72
5Y P/E Exit HK$67.42 HK$109.35 HK$163.81 68
10Y Revenue Exit HK$80.24 HK$130.81 HK$156.51 66
10Y EBITDA Exit HK$87.13 HK$147.99 HK$247.47 64
10Y P/E Exit HK$82.51 HK$134.34 HK$213.31 61
Earnings-Based
Graham-Dodd HK$11.19 HK$78.01 HK$109.47 61
Lynch FV HK$40.30 HK$57.57 HK$74.84 59
PEG = 1.0 HK$40.30 HK$57.57 HK$74.84 55
EPV HK$38.28 HK$41.24 HK$43.84 74
Multiples
P/E Multiple HK$27.14 HK$36.19 HK$45.24 63
P/S Multiple HK$20.97 HK$27.96 HK$34.95 58
P/B Multiple HK$83.03 HK$110.71 HK$138.39 55
EV/EBIT HK$52.69 HK$63.59 HK$74.48 66
EV/EBITDA HK$55.45 HK$67.27 HK$79.08 67
EV/Revenue HK$43.34 HK$53.33 HK$63.33 54
Asset-Based
NCAV (Graham) HK$8.92 HK$13.52 HK$16.90 54
Growth DCF
Growth DCF HK$111.27 HK$202.39 HK$352.47 73
Rev-Margin DCF HK$69.94 HK$99.93 HK$163.40 69
Economic Profit
Residual Income HK$20.08 HK$20.99 HK$23.02 68
ROIC Compounder HK$43.28 HK$54.93 HK$70.42 70
Growth Earnings
Growth-Adj P/E HK$53.50 HK$76.42 HK$99.35 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 76/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 49
How much profit the company makes from its sales and capital
Quality Growth 82
Are margins and returns getting better?
Cashflow 83
Do the profits arrive as real cash?
Financial strength 93
Debt, balance sheet and risk of trouble
Investment 83
Does it invest with discipline instead of growing at any price?
Low Volatility 67
How calm the share price moves, does not count
Price momentum 66
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 86
Distance to the 52-week high, does not count
New shares 53
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 92/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+40.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+55.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+76.9%
Start year 2020 (pandemic). Over 10 years: +89.8% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+67.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−536.7% (2020) → 8.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

Growth Forecast

A lot of optimism in the price
The price assumes less growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+23.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+15.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in USD, USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +20.2% a year for the price and +12.4% for the forecasts.
Forecast 2026 (sales)+26.4%
Forecast 2027 (sales)+14.9%
Projected 2028 (sales)+13.3%
Projected 2029 (sales)+11.7%
Projected 2030 (sales)+10.1%

6160 screens overvalued: fair value 38% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Recent news

News mood ⓘNews mood, the average tone of recent news (100 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.

Compare BeOne Medicines AG with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 8/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 76 · Top 25%
Fair Value upside −38.4% · Above median
Profitability
Return on equity (12 months) 18.4% · Top 25%
Return on assets 3.5% · Above median
Net margin (12 months) 13.9% · Above median
Operating margin (12 months) 22.2% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 33.8% · Top 25%
Balance sheet
Debt / equity 0.22× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 52.1× · Pricier than median
P/B 10.93× · Priciest 25%
P/S (12 months) 7.21× · Pricier than median
Price / free cash flow (fiscal year) 50.5× · Pricier than median
EV/EBITDA 33.1× · Priciest 25%
PEG 0.86× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)74 · sector 0
HEALTH (low debt)89 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs 6160
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs 6160
Samsung Biologics Co 207940 1,510,000 KRW 1,667,600 KRW +10% vs 6160
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs 6160
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs 6160
WuXi Biologics (Cayman) Inc 2269 HK$48.92 HK$52.38 +7% vs 6160
argenx SE ARGX $927.21 $908.40 −2% vs 6160
CSL Limited CSL A$200.77 A$183.04 −9% vs 6160
Celltrion, Inc 068270 210,000 KRW 74,945 KRW −64% vs 6160
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs 6160

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

BeOne Medicines AG: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "BeOne Medicines AG Fair Value". https://www.fairvalue-calculator.com/stock/6160

Frequently asked questions

Is BeOne Medicines AG (6160) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of HK$152.80 versus a price of HK$248.20, about 38% lower (overvalued).
What is the fair value of 6160?
Our model-based fair value for BeOne Medicines AG is HK$152.80 (as of Nov 9, 2026), built from audited fundamentals. The current price: HK$248.20.
What is the quality score of 6160?
BeOne Medicines AG has a Quality Score of 76/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BeOne Medicines AG (6160)?
Our model-based price target is the fair value of HK$152.80 (as of Nov 9, 2026) from 24 valuation models. Cautious scenario HK$106.96, optimistic scenario HK$198.64. It is a calculation from audited fundamentals, not an analyst target.
What is the BeOne Medicines AG stock forecast for 2026?
Our models put fair value at HK$152.80, about 38% lower versus a price of HK$248.20 (overvalued). Cautious scenario HK$106.96, optimistic scenario HK$198.64. The calculation is refreshed regularly with new filings.
What is the revenue of BeOne Medicines AG (6160)?
BeOne Medicines AG reported trailing-twelve-month revenue of about $6.6B (latest available figure, as of Nov 9, 2026).
What growth is priced into BeOne Medicines AG (6160)?
For today's price to be fair in a discounted-cash-flow model, BeOne Medicines AG would have to grow free cash flow by +23.0 % per year for five years (discount rate 8.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +76.9 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of 6160 use?
Our models discount BeOne Medicines AG at 8.9 %: a base by market capitalisation (large), damped by beta 0.63, country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For BeOne Medicines AG that is +23.0 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.9 %) and the same formula as our fair value.
How much growth has BeOne Medicines AG (6160) delivered so far?
Over the past 5 years revenue at BeOne Medicines AG grew +76.9 % a year. The price currently implies free-cash-flow growth of +23.0 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of BeOne Medicines AG (6160) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into BeOne Medicines AG (+23.0 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of BeOne Medicines AG (6160)?
The free-cash-flow yield on the price is 1.98 %: that much free cash flow BeOne Medicines AG produces per unit of market value. When it exceeds the discount rate of our models (8.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of BeOne Medicines AG (6160)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BeOne Medicines AG it is HK$152.80 per share (as of Nov 9, 2026), against a price of HK$248.20. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is BeOne Medicines AG stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 6160 trades above its calculated fair value: price HK$248.20, fair value HK$152.80, a gap of about −38% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6160?
No. The price is what the market pays today (HK$248.20); the fair value is what the company's own numbers justify (HK$152.80). For BeOne Medicines AG the two are HK$95.40 per share apart. That gap is exactly why we show both numbers side by side.
How much is BeOne Medicines AG worth?
The market values BeOne Medicines AG at about HK$374B (market capitalisation, as of Nov 9, 2026). Per share that is HK$248.20; our models calculate a fair value of HK$152.80 per share.
What do the bullish and bearish scenarios say about 6160?
Our models span a range for BeOne Medicines AG: cautious scenario HK$106.96, base HK$152.80, optimistic HK$198.64 per share (as of Nov 9, 2026, price HK$248.20). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6160?
BeOne Medicines AG trades at a price-to-earnings ratio of 52.1 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$152.80 is built from several models across several years. Other multiples: PEG 0.9, P/B 10.9, P/S 7.2, EV/EBITDA 33.1.
What is the PEG ratio of 6160?
The PEG ratio of BeOne Medicines AG is 0.86 (P/E divided by earnings growth, as of Nov 9, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of BeOne Medicines AG (6160)?
Balance-sheet figures for BeOne Medicines AG (as of Nov 9, 2026): return on equity 18.4%, debt of 0.22 per unit of equity. They feed the Quality Score of 76/100, which measures business quality independently of the share price.
How far is 6160 from its 52-week high?
BeOne Medicines AG trades at HK$248.20, at its 52-week high of HK$248.60 and 60% above the low of HK$155.40 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of HK$152.80 is for.
Which stocks are comparable to BeOne Medicines AG?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BeOne Medicines AG stock attractive at the current price?
The data as of Nov 9, 2026: price HK$248.20, calculated fair value HK$152.80 (−38%), Quality Score 76/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6160 calculated?
We run BeOne Medicines AG through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of HK$152.80 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. BeOne Medicines AG itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BeOne Medicines AG (6160)?
The closing price on Nov 9, 2026 was HK$248.20. Our model-based fair value is HK$152.80, about 38% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BeOne Medicines AG right now?
A high-quality business (quality 76/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. The price sits above even our optimistic bull case (HK$198.64). The favourable scenario is already priced in. A fairly wide model range (HK$106.96 to HK$198.64) leaves room in how you read the outcome.

Key figures of BeOne Medicines AG

How large is the market capitalisation of BeOne Medicines AG (6160)?
The market capitalisation of BeOne Medicines AG is HK$374B (≈ $47.7B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BeOne Medicines AG (6160)?
The price-to-sales ratio of BeOne Medicines AG is 2.80 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BeOne Medicines AG (6160)?
Earnings per share at BeOne Medicines AG are HK$2.76 (price ÷ EPS = P/E 52.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of BeOne Medicines AG (6160)?
The net margin of BeOne Medicines AG is 5.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BeOne Medicines AG (6160)?
The return on equity (ROE) of BeOne Medicines AG is 18.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BeOne Medicines AG (6160)?
On an EBIT basis the return on assets of BeOne Medicines AG is −13.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BeOne Medicines AG (6160)?
The operating margin of BeOne Medicines AG is 22.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BeOne Medicines AG (6160)?
Revenue at BeOne Medicines AG is growing +33.8% versus a year earlier (3y avg +55.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at BeOne Medicines AG (6160)?
Earnings per share at BeOne Medicines AG are growing +213% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does BeOne Medicines AG (6160) hold?
BeOne Medicines AG holds more cash than debt, $3.5B net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch BeOne Medicines AG in the live analysis

One click puts BeOne Medicines AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.